BMY241025P57000
- 4.50
- -1.95-30.23%
Bristol-Myers Squibb Newsroom
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $60 From $57
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Bristol-Myers Squibb: Hold Rating With Anticipated Revenue Outperformance Offset by Generic Competition Concerns
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $54
TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $59
Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
Bristol-Myers Squibb Analyst Ratings
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $43
Barclays Sticks to Their Sell Rating for Bristol-Myers Squibb (BMY)
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $42, Maintains Underweight Rating
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
BMO Capital raises bristol-myers squibb's target price to $53.
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $60
Bristol-Myers Squibb Analyst Ratings
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $57
BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $53 From $48, Maintains Market Perform Rating
Truist Financial Gives a Buy Rating to Bristol-Myers Squibb (BMY)